Pemoline-associated hepatic failure: A critical analysis of the literature

Pediatric Neurology

Volumn 16, Issue 1, 1997, Pages 14-16

  Shevell, Michael ^a,b   Schreiber, Richard ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MONTREAL CHILDREN S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; LIVER ENZYME; METHYLPHENIDATE; PEMOLINE; PEMOLINE MAGNESIUM;

ANOREXIA; ATTENTION DEFICIT DISORDER; BILIRUBIN BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; DATA BASE; ENZYME BLOOD LEVEL; HUMAN; LIVER BIOPSY; LIVER FAILURE; LIVER TOXICITY; MEDICAL RECORD; META ANALYSIS; NAUSEA; PRIORITY JOURNAL; REVIEW; VOMITING;

EID: 0031055471     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0887-8994(96)00266-4     Document Type: Review

References (22)

1. [1] Swanson JM, Lerner M, Williams L. More frequent diagnosis of ADHD disorder (Letter). N Engl J Med 1995;333:944.
2. [2] Simeon JG, Wiggins DM, Williams E. World wide use of psychotropic drugs in child and adolescent psychiatric disorders. Prog Neuro Psychopharmacol Biol Psychiatry 1995;19:455-65.
3. [3] Berkovitch M, Pope E, Phillips J, Koren G. Pemoline-associated fulminant liver failure: Testing the evidence for causation. Clin Pharmacol Ther 1995;57:696-8.
4. [4] Jaffe SL. Pemoline and liver function (Letter). J Am Acad Child Adolesc Psychiatry 1989;28:45.
5. [5] Nehra A, Mullick F, Ishak KG, Zimmerman HJ. Pemoline-associated hepatic injury. Gastroenterology 1990;99:1517-9.
6. [6] Helal A. Personal communication, June 18, 1996.
7. [7] White GG. Personal communication, July 8, 1996.
8. [8] Tolman KG, Freston JW, Berenson MM, Sanella JJ. Hepatotoxicity due to pemoline. Report of two cases. Digestion 1973;9:532-9.
9. [9] Patterson JF. Hepatitis associated with pemoline (Letter). South Med J 1984;77:938.
10. [10] Pratt DS, Dubois RS. Hepatotoxicity due to pemoline (Cylert): A report of two cases. J Pediatr Gastroenterol Nutr 1990;10:239-41.
11. [11] Elitsur Y. Pemoline (Cylert)-induced hepatotoxicity (Letter). J Pediatr Gastroenterol Nutr 1990;11:143-4.
12. [12] Sallee F, Stiller R, Paree J, Bates T. Oral pemoline kinetics in hyperactive children. Clin Pharmacol Ther 1985;37:606-09.
13. [13] Bernuau J, Rueff B, Benhamou JP. Fulminant and subfulminant liver failure: Definitions and causes. Semin Liver Dis 1986;6:97-106.
14. [14] Lloyd-Still JD. Mortality from liver disease in children: Implications for hepatic transplantation programs. Am J Dis Child 1985;139: 381-4.
15. [15] Psarcharopoulos HT, Mowat A, Davies M, Portmann B, Silk DBA, Williams R. Fulminant hepatic failure in childhood. Arch Dis Child 1980;55:252-8.
16. [16] DuPaul GJ, Barkley RA. Medication therapy. In: Barkley RA, ed, Attention deficit hyperactivity disorder: A handbook for diagnosis and treatment. New York: Guilford Press, 1990:573-612.
17. [17] Safer DJ, Krager JM. A survey of medication treatment for hyperactive/inattentive students. JAMA 1988;260:2256-58.
18. [18] Devictor D, Deplanques L, Debray D, et al. Emergency liver transplantation for fulminant hepatic failure in infants and children. Hepatology 1992;16:1156-62.
19. [19] Spielberg SP, Gordon GB, Blake DA. Predisposition to phenytoin hepatotoxicity assessed in vitro. Engl J Med 1981;305:722-7.
20. [20] Cylert. In: Gillis MC, ed. Compendium of pharmaceuticals and specialties, 31st ed. Ottawa: The Canadian Pharmaceutical Association, 1996:341.
21. [21] Camfield P, Camfield C. Acute and chronic toxicity of anti-epileptic medications: A selective review. Can J Neurol Sci 1994;21:S7-11.
22. [22] Bohan TP, McDonald II, Konig S, Helton E. Treatment and clinical characteristics of valproate induced hepatotoxicity. Ann Neurol 1995;38:505-6.